Global Dendritic Cell Cancer Vaccine Market Size & Outlook
Global dendritic cell cancer vaccine market, 2018-2030 (US$M)
Related Markets
Global dendritic cell cancer vaccine market highlights
- The global dendritic cell cancer vaccine market generated a revenue of USD 652.5 million in 2023 and is expected to reach USD 1,458.4 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 12.2% by 2030.
- In terms of segment, sipuleucel-t (provenge) accounted for a revenue of USD 550.7 million in 2023.
- Other Vector Type is the most lucrative vector type segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 652.5 million |
| Market revenue in 2030 | USD 1,458.4 million |
| Growth rate | 12.2% (CAGR from 2023 to 2030) |
| Largest segment | Sipuleucel-t (provenge) |
| Fastest growing segment | Other Vector Type |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sipuleucel-T (Provenge), CreaVax, Other Vector Type |
Other key industry trends
- In terms of revenue, the North America accounted for 61.0% of the global dendritic cell cancer vaccine market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, UK is the fastest growing regional market and is projected to reach USD 177.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Dendritic Cell Cancer Vaccine Market Scope
Dendritic Cell Cancer Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global dendritic cell cancer vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dendritic cell cancer vaccine market will help companies and investors design strategic landscapes.
Sipuleucel-t (provenge) was the largest segment with a revenue share of 84.4% in 2023. Horizon Databook has segmented the Global dendritic cell cancer vaccine market based on sipuleucel-t (provenge), creavax, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Dendritic Cell Cancer Vaccine Vector Type Outlook (Revenue, USD Million, 2018-2030)
- Sipuleucel-T (Provenge)
- CreaVax
- Other Vector Type
- Global Dendritic Cell Cancer Vaccine Indication Outlook (Revenue, USD Million, 2018-2030)
- Pediatrics
- Adults
Reasons to subscribe to Global dendritic cell cancer vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global dendritic cell cancer vaccine market databook
-
Our clientele includes a mix of dendritic cell cancer vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global dendritic cell cancer vaccine market , including forecasts for subscribers. This global databook contains high-level insights into Global dendritic cell cancer vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global dendritic cell cancer vaccine market outlook size, by region, 2018-2030 (US$M)
Top 10 countries: Dendritic cell cancer vaccine market size, 2023 (US$M)
Global dendritic cell cancer vaccine market share, by vector type, 2023 & 2030 (%, US$M)
Dendritic cell cancer vaccine market: Opportunity assessment by country
Global dendritic cell cancer vaccine market, by region, 2023 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
